Allena Pharmaceuticals Inc
NASDAQ:ALNA
Intrinsic Value
Allena Pharmaceuticals, Inc. engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ALNA.
Allena Pharmaceuticals Inc's market capitalization is 1.2m USD.
ALNA stock price is 0.0112 USD.
ALNA.
ALNA. Open DCF Valuation
ALNA. Open Relative Valuation
ALNA.
ALNA has negative Free Cash Flow for the last twelve months.
ALNA's long-term assets (18m USD) exceed its long-term liabilties (14m USD).
ALNA's short-term assets (16m USD) exceed its short-term liabilties (10m USD).
ALNA has negative Operating Income for the last twelve months.
ALNA has negative Net Income for the last twelve months.
ALNA's ROE (Return on Equity) has significantly decreased in the last 3 years from -216% to -541%, and is approaching profitability.
ALNA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -2 581% to -816%, and is approaching profitability.
ALNA's ROE (Return on Equity) for the past 12 months is negative and is equal to -541%.
ALNA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -816%.
ALNA has negative three-year average ROE (Return on Equity): -157%. The company is not efficient at transforming stockholders' equity into net income.
ALNA has negative three-year average ROIC (Return on Invested Capital): -3 104%. The company is not efficient at using invested capital to generate operating income.
ALNA's D/E (Debt to Equity) is very low and is equal to 0.
ALNA's Altman Z-Score is very low and is equal to -27.72.
ALNA doesn't generate enough operating income (-41m USD) to safely cover interest payments on its debt (953k USD).
Fundamental Analysis
Allena Pharmaceuticals Inc
Balance Sheet Decomposition
Allena Pharmaceuticals Inc
| Current Assets | 16.5m |
| Cash & Short-Term Investments | 6.6m |
| Other Current Assets | 9.9m |
| Non-Current Assets | 1.3m |
| PP&E | 1.2m |
| Other Non-Current Assets | 123k |
| Current Liabilities | 10.4m |
| Accounts Payable | 2.3m |
| Accrued Liabilities | 3.3m |
| Other Current Liabilities | 4.9m |
| Non-Current Liabilities | 3.6m |
| Other Non-Current Liabilities | 3.6m |
Earnings Waterfall
Allena Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-41m
USD
|
|
Operating Income
|
-41m
USD
|
|
Other Expenses
|
-2.3m
USD
|
|
Net Income
|
-43.3m
USD
|
Free Cash Flow Analysis
Allena Pharmaceuticals Inc
ALNA Profitability Score
Profitability Due Diligence
Allena Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Allena Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ALNA Solvency Score
Solvency Due Diligence
Allena Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Allena Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALNA Price Targets Summary
Allena Pharmaceuticals Inc
Ownership
ALNA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ALNA Price
Allena Pharmaceuticals Inc
| Average Annual Return | -56.01% |
| Standard Deviation of Annual Returns | 1.05% |
| Max Drawdown | -100% |
| Market Capitalization | 1.2m USD |
| Shares Outstanding | 107 725 000 |
| Percentage of Shares Shorted | 8.54% |
Company Profile
Allena Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Allena Pharmaceuticals, Inc. engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Newton, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa studies for ALLN-346.
You don't have any saved screeners yet
